In the PREDIAN study, it was observed that adding pentoxifylline to RAS blockade therapy led to a reduction in the urinary excretion of TNF-α, which was inversely related to the eGFR in patients with stage 3 and 4 chronic kidney disease [54]. Here, TNF is linked to chronic kidney disease.